

Medtronic

ClosureFast™

Radiofrequency Ablation System§

Now in
6F

Proven procedure^{3,5} Lower profile

Proven in millions of patients,¹ the ClosureFast RFA system is now available in 6F, for better flexibility and easier navigation, even in tortuous veins.^{†‡}

Built on technology you know and trust

2.5 M+

patients treated
worldwide¹

200+

published articles
and clinical studies²


91.9%

closure rate at 5 years³




Now in 6F, designed for^{†‡}:


Enhanced **flexibility**



Improved **navigation**



Increased **kink-resistance**



Adverse events may include hematoma, phlebitis, skin injury, nerve injury, thrombophlebitis, thrombosis, and/or pulmonary embolism.

†Compared to ClosureFast 7F catheter and Venclose™[‡] catheter in bench testing.

‡Bench test data on file at Medtronic. N = 15 Venclose™[‡] catheters and 30 each ClosureFast 6F and 7F catheters. Bench tests may not be indicative of clinical performance.

§The ClosureFast System consists of two main components, licenced as ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter and Radiofrequency Generator

◇Some products/indications/therapy areas may not be licensed in accordance with Canadian Law.



Longer 8 cm heating length

Designed for procedural efficiency

Gap-free thermal ablation

Patented overlap of 0.5 cm at each treatment segment eliminates gaps between segments – for lasting vein closure.^{3,4}

Comfortable patient experience

Short, comfortable recovery means a quick return to everyday activities.⁵⁻⁷

The ClosureFast 6F catheter is designed to provide the same safety and efficacy, quality of life, and patient outcomes as demonstrated by the ClosureFast 7F catheter.⁸



Adverse events may include hematoma, phlebitis, skin injury, nerve injury, thrombophlebitis, thrombosis, and/or pulmonary embolism.

1 ClosureFast Procedures. Medtronic data on file, 2022.

2 Medtronic ClosureFast Procedure Publications. Medtronic data on file, 2022.

3 Proebstle TM, Alm BJ, Göckeritz O, et al. Five-year results from the prospective European multi-centre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. *Br J Surg*. February 2015;102(3):212-218. ClosureFast 7F catheter used in this study.

4 ClosureFast and ClosureFast RFS Patents. Medtronic data on file, 2022.

5 Lurie F, Creton D, Eklof B, et al. Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population (EVOLVE Study). *J Vasc Surg*. August 2003;38(2):207-214.

6 Hinchliffe RJ, Ubhi J, Beech A, Ellison J, Braithwaite BD. A prospective randomised controlled trial of VNUS closure versus surgery for the treatment of recurrent long saphenous varicose veins. *Eur J Vasc Endovasc Surg*. February 2006;31(2):212-218.

7 Rasmussen LH, Lawaetz M, Bjoern L, Vennits B, Blemings A, Eklof B. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. *Br J Surg*. August 2011;98(8):1079-1087.

8 ClosureFast 6F is designed to provide the same outcomes as established by ClosureFast 7F catheter. Symptom relief and return to normal activities data are from ClosureFast 7F studies.

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use.

Medtronic

99 Hereford Street
Brampton, Ontario, L6Y 0R3
Toll-free: 800.268.5346
Tel: 905.460.3800

medtronic.ca

©2024 Medtronic. All rights reserved. Medtronic, Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. TM*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. UC202311844aEC CA-CTL-0329-E Rev. 05/2024